Eintrag weiter verarbeiten
Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV
Gespeichert in:
| Zeitschriftentitel: | Clinical Infectious Diseases |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , , , , |
| In: | Clinical Infectious Diseases, 68, 2019, 11, S. 1823-1830 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Oxford University Press (OUP)
|
| Schlagwörter: |
| author_facet |
Evans, Scott R Tran, Thuy Tien T Hujer, Andrea M Hill, Carol B Hujer, Kristine M Mediavilla, Jose R Manca, Claudia Domitrovic, T Nicholas Perez, Federico Farmer, Michael Pitzer, Kelsey M Wilson, Brigid M Kreiswirth, Barry N Patel, Robin Jacobs, Michael R Chen, Liang Fowler, Vance G Chambers, Henry F Bonomo, Robert A Evans, Scott R Tran, Thuy Tien T Hujer, Andrea M Hill, Carol B Hujer, Kristine M Mediavilla, Jose R Manca, Claudia Domitrovic, T Nicholas Perez, Federico Farmer, Michael Pitzer, Kelsey M Wilson, Brigid M Kreiswirth, Barry N Patel, Robin Jacobs, Michael R Chen, Liang Fowler, Vance G Chambers, Henry F Bonomo, Robert A |
|---|---|
| author |
Evans, Scott R Tran, Thuy Tien T Hujer, Andrea M Hill, Carol B Hujer, Kristine M Mediavilla, Jose R Manca, Claudia Domitrovic, T Nicholas Perez, Federico Farmer, Michael Pitzer, Kelsey M Wilson, Brigid M Kreiswirth, Barry N Patel, Robin Jacobs, Michael R Chen, Liang Fowler, Vance G Chambers, Henry F Bonomo, Robert A |
| spellingShingle |
Evans, Scott R Tran, Thuy Tien T Hujer, Andrea M Hill, Carol B Hujer, Kristine M Mediavilla, Jose R Manca, Claudia Domitrovic, T Nicholas Perez, Federico Farmer, Michael Pitzer, Kelsey M Wilson, Brigid M Kreiswirth, Barry N Patel, Robin Jacobs, Michael R Chen, Liang Fowler, Vance G Chambers, Henry F Bonomo, Robert A Clinical Infectious Diseases Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV Infectious Diseases Microbiology (medical) |
| author_sort |
evans, scott r |
| spelling |
Evans, Scott R Tran, Thuy Tien T Hujer, Andrea M Hill, Carol B Hujer, Kristine M Mediavilla, Jose R Manca, Claudia Domitrovic, T Nicholas Perez, Federico Farmer, Michael Pitzer, Kelsey M Wilson, Brigid M Kreiswirth, Barry N Patel, Robin Jacobs, Michael R Chen, Liang Fowler, Vance G Chambers, Henry F Bonomo, Robert A 1058-4838 1537-6591 Oxford University Press (OUP) Infectious Diseases Microbiology (medical) http://dx.doi.org/10.1093/cid/ciy801 <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Overcoming β-lactam resistance in pathogens such as Pseudomonas aeruginosa is a major clinical challenge. Rapid molecular diagnostics (RMDs) have the potential to inform selection of empiric therapy in patients infected by P. aeruginosa.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>In this study, we used a heterogeneous collection of 197 P. aeruginosa that included multidrug-resistant isolates to determine whether 2 representative RMDs (Acuitas Resistome test and VERIGENE gram-negative blood culture test) could identify susceptibility to 2 newer β-lactam/β-lactamase inhibitor (BL-BLI) combinations, ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (TOL/TAZO).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We found that the studied RMD platforms were able to correctly identify BL-BLI susceptibility (susceptibility sensitivity, 100%; 95% confidence interval [CI], 97%, 100%) for both BLs-BLIs. However, their ability to detect resistance to these BLs-BLIs was lower (resistance sensitivity, 66%; 95% CI, 52%, 78% for TOL/TAZO and 33%; 95% CI, 20%, 49% for CZA).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The diagnostic platforms studied showed the most potential in scenarios where a resistance gene was detected or in scenarios where a resistance gene was not detected and the prevalence of resistance to TOL/TAZO or CZA is known to be low. Clinicians need to be mindful of the benefits and risks that result from empiric treatment decisions that are based on resistance gene detection in P. aeruginosa, acknowledging that such decisions are impacted by the prevalence of resistance, which varies temporally and geographically.</jats:p></jats:sec> Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV Clinical Infectious Diseases |
| doi_str_mv |
10.1093/cid/ciy801 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin Biologie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9jaWQvY2l5ODAx |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9jaWQvY2l5ODAx |
| institution |
DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-105 |
| imprint |
Oxford University Press (OUP), 2019 |
| imprint_str_mv |
Oxford University Press (OUP), 2019 |
| issn |
1537-6591 1058-4838 |
| issn_str_mv |
1537-6591 1058-4838 |
| language |
English |
| mega_collection |
Oxford University Press (OUP) (CrossRef) |
| match_str |
evans2019rapidmoleculardiagnosticstoinformempiricuseofceftazidimeavibactamandceftolozanetazobactamagainstpseudomonasaeruginosaprimersiv |
| publishDateSort |
2019 |
| publisher |
Oxford University Press (OUP) |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical Infectious Diseases |
| source_id |
49 |
| title |
Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV |
| title_unstemmed |
Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV |
| title_full |
Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV |
| title_fullStr |
Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV |
| title_full_unstemmed |
Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV |
| title_short |
Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV |
| title_sort |
rapid molecular diagnostics to inform empiric use of ceftazidime/avibactam and ceftolozane/tazobactam against pseudomonas aeruginosa: primers iv |
| topic |
Infectious Diseases Microbiology (medical) |
| url |
http://dx.doi.org/10.1093/cid/ciy801 |
| publishDate |
2019 |
| physical |
1823-1830 |
| description |
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Overcoming β-lactam resistance in pathogens such as Pseudomonas aeruginosa is a major clinical challenge. Rapid molecular diagnostics (RMDs) have the potential to inform selection of empiric therapy in patients infected by P. aeruginosa.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>In this study, we used a heterogeneous collection of 197 P. aeruginosa that included multidrug-resistant isolates to determine whether 2 representative RMDs (Acuitas Resistome test and VERIGENE gram-negative blood culture test) could identify susceptibility to 2 newer β-lactam/β-lactamase inhibitor (BL-BLI) combinations, ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (TOL/TAZO).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We found that the studied RMD platforms were able to correctly identify BL-BLI susceptibility (susceptibility sensitivity, 100%; 95% confidence interval [CI], 97%, 100%) for both BLs-BLIs. However, their ability to detect resistance to these BLs-BLIs was lower (resistance sensitivity, 66%; 95% CI, 52%, 78% for TOL/TAZO and 33%; 95% CI, 20%, 49% for CZA).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The diagnostic platforms studied showed the most potential in scenarios where a resistance gene was detected or in scenarios where a resistance gene was not detected and the prevalence of resistance to TOL/TAZO or CZA is known to be low. Clinicians need to be mindful of the benefits and risks that result from empiric treatment decisions that are based on resistance gene detection in P. aeruginosa, acknowledging that such decisions are impacted by the prevalence of resistance, which varies temporally and geographically.</jats:p></jats:sec> |
| container_issue |
11 |
| container_start_page |
1823 |
| container_title |
Clinical Infectious Diseases |
| container_volume |
68 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792341254778912777 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:15:55.86Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Rapid+Molecular+Diagnostics+to+Inform+Empiric+Use+of+Ceftazidime%2FAvibactam+and+Ceftolozane%2FTazobactam+Against+Pseudomonas+aeruginosa%3A+PRIMERS+IV&rft.date=2019-05-17&genre=article&issn=1537-6591&volume=68&issue=11&spage=1823&epage=1830&pages=1823-1830&jtitle=Clinical+Infectious+Diseases&atitle=Rapid+Molecular+Diagnostics+to+Inform+Empiric+Use+of+Ceftazidime%2FAvibactam+and+Ceftolozane%2FTazobactam+Against+Pseudomonas+aeruginosa%3A+PRIMERS+IV&aulast=Bonomo&aufirst=Robert+A&rft_id=info%3Adoi%2F10.1093%2Fcid%2Fciy801&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792341254778912777 |
| author | Evans, Scott R, Tran, Thuy Tien T, Hujer, Andrea M, Hill, Carol B, Hujer, Kristine M, Mediavilla, Jose R, Manca, Claudia, Domitrovic, T Nicholas, Perez, Federico, Farmer, Michael, Pitzer, Kelsey M, Wilson, Brigid M, Kreiswirth, Barry N, Patel, Robin, Jacobs, Michael R, Chen, Liang, Fowler, Vance G, Chambers, Henry F, Bonomo, Robert A |
| author_facet | Evans, Scott R, Tran, Thuy Tien T, Hujer, Andrea M, Hill, Carol B, Hujer, Kristine M, Mediavilla, Jose R, Manca, Claudia, Domitrovic, T Nicholas, Perez, Federico, Farmer, Michael, Pitzer, Kelsey M, Wilson, Brigid M, Kreiswirth, Barry N, Patel, Robin, Jacobs, Michael R, Chen, Liang, Fowler, Vance G, Chambers, Henry F, Bonomo, Robert A, Evans, Scott R, Tran, Thuy Tien T, Hujer, Andrea M, Hill, Carol B, Hujer, Kristine M, Mediavilla, Jose R, Manca, Claudia, Domitrovic, T Nicholas, Perez, Federico, Farmer, Michael, Pitzer, Kelsey M, Wilson, Brigid M, Kreiswirth, Barry N, Patel, Robin, Jacobs, Michael R, Chen, Liang, Fowler, Vance G, Chambers, Henry F, Bonomo, Robert A |
| author_sort | evans, scott r |
| container_issue | 11 |
| container_start_page | 1823 |
| container_title | Clinical Infectious Diseases |
| container_volume | 68 |
| description | <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Overcoming β-lactam resistance in pathogens such as Pseudomonas aeruginosa is a major clinical challenge. Rapid molecular diagnostics (RMDs) have the potential to inform selection of empiric therapy in patients infected by P. aeruginosa.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>In this study, we used a heterogeneous collection of 197 P. aeruginosa that included multidrug-resistant isolates to determine whether 2 representative RMDs (Acuitas Resistome test and VERIGENE gram-negative blood culture test) could identify susceptibility to 2 newer β-lactam/β-lactamase inhibitor (BL-BLI) combinations, ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (TOL/TAZO).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We found that the studied RMD platforms were able to correctly identify BL-BLI susceptibility (susceptibility sensitivity, 100%; 95% confidence interval [CI], 97%, 100%) for both BLs-BLIs. However, their ability to detect resistance to these BLs-BLIs was lower (resistance sensitivity, 66%; 95% CI, 52%, 78% for TOL/TAZO and 33%; 95% CI, 20%, 49% for CZA).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The diagnostic platforms studied showed the most potential in scenarios where a resistance gene was detected or in scenarios where a resistance gene was not detected and the prevalence of resistance to TOL/TAZO or CZA is known to be low. Clinicians need to be mindful of the benefits and risks that result from empiric treatment decisions that are based on resistance gene detection in P. aeruginosa, acknowledging that such decisions are impacted by the prevalence of resistance, which varies temporally and geographically.</jats:p></jats:sec> |
| doi_str_mv | 10.1093/cid/ciy801 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin, Biologie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9jaWQvY2l5ODAx |
| imprint | Oxford University Press (OUP), 2019 |
| imprint_str_mv | Oxford University Press (OUP), 2019 |
| institution | DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105 |
| issn | 1537-6591, 1058-4838 |
| issn_str_mv | 1537-6591, 1058-4838 |
| language | English |
| last_indexed | 2024-03-01T16:15:55.86Z |
| match_str | evans2019rapidmoleculardiagnosticstoinformempiricuseofceftazidimeavibactamandceftolozanetazobactamagainstpseudomonasaeruginosaprimersiv |
| mega_collection | Oxford University Press (OUP) (CrossRef) |
| physical | 1823-1830 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Oxford University Press (OUP) |
| record_format | ai |
| recordtype | ai |
| series | Clinical Infectious Diseases |
| source_id | 49 |
| spelling | Evans, Scott R Tran, Thuy Tien T Hujer, Andrea M Hill, Carol B Hujer, Kristine M Mediavilla, Jose R Manca, Claudia Domitrovic, T Nicholas Perez, Federico Farmer, Michael Pitzer, Kelsey M Wilson, Brigid M Kreiswirth, Barry N Patel, Robin Jacobs, Michael R Chen, Liang Fowler, Vance G Chambers, Henry F Bonomo, Robert A 1058-4838 1537-6591 Oxford University Press (OUP) Infectious Diseases Microbiology (medical) http://dx.doi.org/10.1093/cid/ciy801 <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Overcoming β-lactam resistance in pathogens such as Pseudomonas aeruginosa is a major clinical challenge. Rapid molecular diagnostics (RMDs) have the potential to inform selection of empiric therapy in patients infected by P. aeruginosa.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>In this study, we used a heterogeneous collection of 197 P. aeruginosa that included multidrug-resistant isolates to determine whether 2 representative RMDs (Acuitas Resistome test and VERIGENE gram-negative blood culture test) could identify susceptibility to 2 newer β-lactam/β-lactamase inhibitor (BL-BLI) combinations, ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (TOL/TAZO).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We found that the studied RMD platforms were able to correctly identify BL-BLI susceptibility (susceptibility sensitivity, 100%; 95% confidence interval [CI], 97%, 100%) for both BLs-BLIs. However, their ability to detect resistance to these BLs-BLIs was lower (resistance sensitivity, 66%; 95% CI, 52%, 78% for TOL/TAZO and 33%; 95% CI, 20%, 49% for CZA).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The diagnostic platforms studied showed the most potential in scenarios where a resistance gene was detected or in scenarios where a resistance gene was not detected and the prevalence of resistance to TOL/TAZO or CZA is known to be low. Clinicians need to be mindful of the benefits and risks that result from empiric treatment decisions that are based on resistance gene detection in P. aeruginosa, acknowledging that such decisions are impacted by the prevalence of resistance, which varies temporally and geographically.</jats:p></jats:sec> Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV Clinical Infectious Diseases |
| spellingShingle | Evans, Scott R, Tran, Thuy Tien T, Hujer, Andrea M, Hill, Carol B, Hujer, Kristine M, Mediavilla, Jose R, Manca, Claudia, Domitrovic, T Nicholas, Perez, Federico, Farmer, Michael, Pitzer, Kelsey M, Wilson, Brigid M, Kreiswirth, Barry N, Patel, Robin, Jacobs, Michael R, Chen, Liang, Fowler, Vance G, Chambers, Henry F, Bonomo, Robert A, Clinical Infectious Diseases, Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV, Infectious Diseases, Microbiology (medical) |
| title | Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV |
| title_full | Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV |
| title_fullStr | Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV |
| title_full_unstemmed | Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV |
| title_short | Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV |
| title_sort | rapid molecular diagnostics to inform empiric use of ceftazidime/avibactam and ceftolozane/tazobactam against pseudomonas aeruginosa: primers iv |
| title_unstemmed | Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV |
| topic | Infectious Diseases, Microbiology (medical) |
| url | http://dx.doi.org/10.1093/cid/ciy801 |